Glycopyrrolate and formoterol fumarate for the treatment of COPD.
INTRODUCTION
Long acting bronchodilators are nowadays the central treatment for management of stable COPD. Several combinations exist within the market with different formulation devices. This article reviews a recent dual combination of glycopyrronium and formoterol fumarate in an innovative pMDI-fixed dual combination, Bevespi® Aerosphere.


AREAS COVERED
This article explored the literature to understand the place of this novel combination and unique delivery drug device in today's therapeutic arsenal. Clinical efficacy and safety have been evaluated through the different clinical trials published in public databases.


EXPERT OPINION
Within the fixed-dose combinations, Glycopyrrolate and formoterol fumarate offer a credible unique pMDI option to be given twice a day. LABA-LAMA offers an ICS-free alternative in COPD pharmacology which represents an important treatment option given the current debate over whether or not, maintenance triple therapy combined with ICS are benefic in the long term.
['Grillet|Pierre-Edouard|PE|', 'Le Souder|Cosette|C|', 'Rohou|Juliette|J|', 'Cazorla|Olivier|O|', 'Charriot|Jérémy|J|0000-0002-1420-5774', 'Bourdin|Arnaud|A|']
D000280:Administration, Inhalation D001993:Bronchodilator Agents D000068759:Formoterol Fumarate D006024:Glycopyrrolate D006801:Humans D029424:Pulmonary Disease, Chronic Obstructive
COPD Bronchodilators pMDI